Jubilant Pharmova Limited (JUBLPHARMA) Price & Analysis

Compare

2 Followers

JUBLPHARMA Stock Chart & Stats

₹1056.10

₹15.25(1.49%)

At close: Jan 08 4:00 PM EST

₹1056.10

₹15.25(1.49%)

Day’s Range― - ―

52-Week Range₹823.70 - ₹1,250.00

Previous CloseN/A

Volume282.20K

Average Volume (3M)7.42K

Market Cap

₹137.99B

Enterprise Value₹159.59B

Total Cash (Recent Filing)₹10.89B

Total Debt (Recent Filing)₹0.00

Price to Earnings (P/E)31.7

Beta1.25

Next Earnings

May 29, 2026

EPS Estimate

6.9

Next Dividend Ex-DateN/A

Dividend Yield0.46%

Share Statistics

EPS (TTM)5.00

Shares Outstanding159,281,140

10 Day Avg. Volume4,911

30 Day Avg. Volume7,424

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)2.33

Price to Sales (P/S)2.01

P/FCF Ratio-334.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

₹1,310.00

Price Target Upside24.04% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)35.3

Revenue Forecast (FY)₹80.99B

Bulls Say, Bears Say

Bulls Say

Diversified Life-sciences Business Mix (CDMO, Radiopharma, Allergy, Generics)A diversified portfolio across CDMO, radiopharmaceuticals, allergy therapy and generics provides multiple, complementary revenue engines. CDMO brings contractual, repeatable manufacturing revenue while niche radiopharma and allergy segments offer higher-value growth, reducing single-market dependency and supporting durable revenues.

Improving Operational Margins With Steady Revenue GrowthSustained improvement in gross and EBIT margins alongside near 9% revenue growth reflects better operational efficiency and scaling of manufacturing and R&D capabilities. Improved operating leverage supports mid-term earnings stability and strengthens the firm's ability to invest in capacity and regulated-market qualifications.

Manageable Leverage And A Solid Equity BaseModerate leverage (D/E ~0.44) and a near-50% equity ratio give financial flexibility to fund capex cycles common in CDMO and radiopharma. An improving ROE (~13.4%) signals better capital efficiency, supporting resilience through investment cycles without excessive refinancing risk over the next several months.

Bears Say

Negative Free Cash Flow Driven By High Capital ExpendituresNegative free cash flow from elevated capex reduces internally available funds for growth or dividends and can force external financing. For a capital-intensive CDMO and radiopharma operator, persistent negative FCF raises execution and liquidity risk and can constrain strategic investments if not reversed.

Low Net Profit Margin And Declining EPSA modest net margin (~11.6%) and steep EPS decline indicate challenges converting operating gains to net earnings. This undermines earnings resilience, limits retained earnings for reinvestment, and signals pressure on per-share profitability that may persist absent sustained margin expansion or cost control.

Exposure To Regulatory Approvals, Compliance And Utilization RiskRevenue and margins depend on successful regulatory approvals, ongoing compliance, and high manufacturing utilization. Delays, compliance issues or underutilized capacity can materially reduce contract wins and recurring throughput, creating structural downside to medium-term revenue and margin forecasts.

Jubilant Pharmova Limited News

Jubilant Pharmova Creates Canadian Arm to Build Branded Generics Business

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an update. Jubilant Pharmova’s step-down subsidiary, Jubilant Generics Limited, has...

2M ago

Jubilant Pharmova Subsidiary to Appeal Rs 9.71 Crore GST Demand, Sees No Material Impact

An update from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now available. Jubilant Pharmova has disclosed that its...

2M ago

Jubilant Pharmova’s Subsidiary to Contest GST Adjudication Order

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an update. Jubilant Pharmova Limited has announced that its wholly...

3M ago

Jubilant Pharmova Appoints New CEO to Lead Therapeutics Subsidiary

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has provided an announcement. Jubilant Pharmova Limited has appointed Daniel J. O’Connor...

3M ago

Jubilant Pharmova Launches ‘Saksham Niveshak’ Campaign for Shareholders

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an announcement. Jubilant Pharmova Limited has launched the ‘Saksham Niveshak’...

4M ago

Jubilant Pharmova Releases Financial Results for Q2 2025

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has issued an announcement. Jubilant Pharmova Limited has announced the publication of...

4M ago

Jubilant Pharmova Reports Unaudited Financial Results for September 2025

An announcement from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) is now available. Jubilant Pharmova Limited announced its unaudited...

4M ago

Jubilant Pharmova Grants Stock Options to Employees

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has provided an update. Jubilant Pharmova Limited’s Board of Directors has approved...

4M ago

Jubilant Pharmova Approves Stock Options to Enhance Employee Retention

The latest announcement is out from Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ). Jubilant Pharmova Limited has announced the...

4M ago

Jubilant Pharmova Launches Initiative to Aid Shareholders in KYC Updates and Dividend Claims

Jubilant Pharmova Limited ( ($IN:JUBLPHARMA) ) has shared an announcement. Jubilant Pharmova Limited has launched an initiative as...

5M ago

JUBLPHARMA FAQ

What was Jubilant Pharmova Limited’s price range in the past 12 months?

Jubilant Pharmova Limited lowest stock price was ₹823.70 and its highest was ₹1250.00 in the past 12 months.

What is Jubilant Pharmova Limited’s market cap?

Jubilant Pharmova Limited’s market cap is ₹137.99B.

When is Jubilant Pharmova Limited’s upcoming earnings report date?

Jubilant Pharmova Limited’s upcoming earnings report date is May 29, 2026 which is in 87 days.

How were Jubilant Pharmova Limited’s earnings last quarter?

Jubilant Pharmova Limited released its earnings results on Feb 06, 2026. The company reported ₹5 earnings per share for the quarter, missing the consensus estimate of ₹8.25 by -₹3.25.

Is Jubilant Pharmova Limited overvalued?

According to Wall Street analysts Jubilant Pharmova Limited’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Jubilant Pharmova Limited pay dividends?

Jubilant Pharmova Limited pays a Annually dividend of ₹5 which represents an annual dividend yield of 0.46%. See more information on Jubilant Pharmova Limited dividends here

What is Jubilant Pharmova Limited’s EPS estimate?

Jubilant Pharmova Limited’s EPS estimate is 6.9.

How many shares outstanding does Jubilant Pharmova Limited have?

Jubilant Pharmova Limited has 159,281,140 shares outstanding.

What happened to Jubilant Pharmova Limited’s price movement after its last earnings report?

Jubilant Pharmova Limited reported an EPS of ₹5 in its last earnings report, missing expectations of ₹8.25. Following the earnings report the stock price went down -4.177%.

Which hedge fund is a major shareholder of Jubilant Pharmova Limited?

Currently, no hedge funds are holding shares in IN:JUBLPHARMA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Jubilant Pharmova Limited

Jubilant Pharmova Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Pharmaceuticals; Contract Research & Development Services; and Proprietary Novel Drugs. The Pharmaceuticals segment engages in the manufacturing and supply of allergy therapy products, contract manufacturing of sterile injectables and non-sterile products, active pharmaceutical ingredients, and solid dosage formulations, as well as sale of radiopharmaceuticals through a network of 48 radio pharmacies in the United States. The Contract Research & Development Services segment provides collaborative research services to pharmaceutical innovators. The Proprietary Novel Drugs segment develops therapies in the areas of oncology and auto-immune disorders. The company was formerly known as Jubilant Life Sciences Limited and changed its name to Jubilant Pharmova Limited in February 2021. The company was incorporated in 1978 and is headquartered in Noida, India.

Jubilant Pharmova Limited (JUBLPHARMA) Earnings & Revenues

Historic Earnings Reports

JUBLPHARMA Stock 12 Month Forecast

Average Price Target

₹1,310.00

▲(24.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"865":"₹865","1088":"₹1,088","1311":"₹1,311","976.5":"₹976.5","1199.5":"₹1,199.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">₹1.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">₹1.31K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1310,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">₹1.31K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[865,976.5,1088,1199.5,1311],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,866.35,900.4769230769231,934.6038461538462,968.7307692307693,1002.8576923076923,1036.9846153846154,1071.1115384615384,1105.2384615384615,1139.3653846153848,1173.4923076923078,1207.6192307692309,1241.746153846154,1275.873076923077,{"y":1310,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,866.35,900.4769230769231,934.6038461538462,968.7307692307693,1002.8576923076923,1036.9846153846154,1071.1115384615384,1105.2384615384615,1139.3653846153848,1173.4923076923078,1207.6192307692309,1241.746153846154,1275.873076923077,{"y":1310,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,866.35,900.4769230769231,934.6038461538462,968.7307692307693,1002.8576923076923,1036.9846153846154,1071.1115384615384,1105.2384615384615,1139.3653846153848,1173.4923076923078,1207.6192307692309,1241.746153846154,1275.873076923077,{"y":1310,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":898.61,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":910.51,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":893.48,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1164.62,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1192.5,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1160.6,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1039.5,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1113.35,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1097.55,"date":1761955200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1106.85,"date":1764547200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":1055.9,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":957.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":866.35,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >